Mesa Labs Q3 revenue -1% to $54.3M; core organic growth 4.6%; net income up 122%

MESA LABORATORIES INC /CO/

2023-Q3 EPS reported $0.06 revenue$163,489,000

Revenues $54,287K, down 1% YoY; organic revenue decline 2.1% due to currency and other headwinds.
Net income $451K ($0.08 diluted EPS) vs $203K in prior year; increase of 122%.
Non-GAAP AOI excluding unusual items $12,856K (24% of revenue), down 7% YoY.
Clinical Genomics revenues $15,585K, down 10% organic; core organic growth 3.3% ex-Sema4 would be 19%.
SDC core organic growth 21.1%; Calibration Solutions impacted by supply chain constraints.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

MESA LABORATORIES INC /CO/ reported three and nine months ended December 31, 2022 results: revenue $54,287, net income $451, EPS $0.08 per diluted share.

Period: three and nine months ended December 31, 2022
Revenue: $54,287
Net income: $451
EPS: $0.08 per diluted share
Result: reported results

Exact text from the filing

3 was 4.6% ● Operating income increased 235% ● Non-GAAP adjusted operating income 1 excluding unusual items decreased 7% Executive Commentary (amounts in thousands) “Revenues of $54,287 in the quarter resulted in an organic revenues decline of 2.1% for the quarter, heavily influenced by currency headwinds across the company, as well as COVID headwinds and the

View on SEC.gov

Browse all earnings releases →

MESA LABORATORIES INC /CO/ filing history →

Source: SEC EDGAR

accession 0001437749-23-002547

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.